# Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

> **NCT04171622** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 25 (estimated)

## Conditions studied

- Metastatic Thyroid Gland Carcinoma
- Poorly Differentiated Thyroid Gland Carcinoma
- Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8
- Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8
- Thyroid Gland Squamous Cell Carcinoma
- Unresectable Thyroid Gland Carcinoma

## Interventions

- **DRUG:** Lenvatinib
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04171622
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-04
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04171622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04171622, "Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04171622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*